Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma

多克隆继发性 FGFR2 突变导致 FGFR2 融合阳性胆管癌患者对 FGFR 抑制产生获得性耐药

阅读：8

作者：Lipika Goyal, Supriya K Saha, Leah Y Liu, Giulia Siravegna, Ignaty Leshchiner, Leanne G Ahronian, Jochen K Lennerz, Phuong Vu, Vikram Deshpande, Avinash Kambadakone, Benedetta Mussolin, Stephanie Reyes, Laura Henderson, Jiaoyuan Elisabeth Sun, Emily E Van Seventer, Joseph M Gurski Jr, Sabrina Baltsc

期刊：

Cancer Discovery

影响因子：

29.700

时间：

2017

起止号：

2017 Mar;7(3):252-263.

doi：

10.1158/2159-8290.CD-16-1000

研究方向：

肿瘤

疾病类型：

胆管癌

Significance

We report the first genetic mechanisms of clinical acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive ICC. Our findings can inform future strategies for detecting resistance mechanisms and inducing more durable remissions in ICC and in the wide variety of cancers where the FGFR pathway is being explored as a therapeutic target. Cancer Discov; 7(3); 252-63. ©2016 AACR.See related commentary by Smyth et al., p. 248This article is highlighted in the In This Issue feature, p. 235.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用；引用内容仅为补充信息，不代表本站立场。

2、若认为本页面引用内容涉及侵权，请及时与本站联系，我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容，需注明“来源：[生知库]”并获得授权；使用引用内容的，需自行联系原作者获得许可。

4、投稿及合作请联系：info@biocloudy.com。